Binu Kandathilparambil Sasi

Binu Kandathilparambil Sasi

Auto-generated profile, based on publicly available information

Binu Kandathilparambil Sasi

Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center San Antonio, San Antonio, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2016 in Blood
Verified
Journal Article
Closed access
PDF file
KBKamil Bojarczuk
Kamil Bojarczuk
BSBinu K. Sasi
Binu K. Sasi
SGStefania Gobessi
Stefania Gobessi
IIIdanna Innocenti
Idanna Innocenti
GPGabriele Pozzato
Gabriele Pozzato
Dimitar EfremovDimitar Efremov
Dimitar Efremov
The Bcl-2 antagonist ABT-199 has demonstrated promising clinical activity in patients with CLL. ABT-199 is strongly cytotoxic against unstimulated peripheral blood CLL cells in vitro, but is much less effective against CLL cells that have received survival signals from the microenvironment. In particular, stimulation of CLL cells with CD40L results in substantial resistance that is mediated by induction of the antiapoptotic Bcl-2 family proteins Bcl-xL and Bfl-1. In the present study we investigated whether resistance to ABT-199 can be conferred by B-cell receptor (BCR) stimulation, which is another important survival signal from the leukemic microenvironment. We show that sustained BCR stimulation results in significant ABT-199-resistance, which correlates with induction of the antiapoptotic protein Mcl-1 and less consistently with downregulation of proapoptotic Bmf, Hrk and BimEL. A major role for Mcl-1 in conferring ABT-199 resistance is additionally supported by knockdown and enforced expression experiments with primary CLL cells. We further show that SYK, BTK and PI3Kδ inhibitors significantly downregulate Mcl-1, but with different efficacy. Complete Mcl-1 downregulation was consistently achieved only with the SYK inhibitors R406 and GS-9973, whereas the BTK inhibitor ibrutinib and the PI3Kδ inhibitor idelalisib in more than half of the cases had only a partial effect. The greater ability of SYK inhibitors to downregulate Mcl-1 correlated with their greater capacity to block BCR-mediated inactivation of GSK-3, a major negative regulator of Mcl-1. The finding that BCR-signaling inhibitors differ in their ability to target Mcl-1 is relevant for the design of clinical trials combining these agents with ABT-199.

2 June 2010 in Nanotechnology
Verified
Journal Article
Closed access
ARAbdul Khaliq Rasheed
Abdul Khaliq Rasheed
PSParshuram J Sonawane
Parshuram J Sonawane
BSBinu K Sasi
Binu K Sasi
BSBhavani S Sahu
Bhavani S Sahu
TPT Pradeep
T Pradeep
NMNitish R Mahapatra
Nitish R Mahapatra
Improvement of the specificity and efficiency of the polymerase chain reaction (PCR) by nanoparticles is an emerging area of research. We observed that TiO(2) nanoparticles of approximately 25 nm diameter caused significant enhancement of PCR efficiency for various types of templates (namely plasmid DNA, genomic DNA and complementary DNA). By a series of experiments, the optimal TiO(2) concentration was determined to be 0.4 nM, which resulted in up to a seven-fold increase in the amount of PCR product. As much as 50% reduction in overall reaction time (by reduction of the number of cycles and the time periods of cycles) was also achieved by utilizing TiO(2) nanoparticles without compromising the PCR yield. Investigations of the mechanism of such PCR enhancement by simulations using the 'Fluent K epsilon turbulent model' provided evidence of faster heat transfer in the presence of TiO(2) nanoparticles. Consistent with these findings, TiO(2) nanoparticles were observed to augment the denaturation of genomic DNA, indicating more efficient thermal conductivity through the reaction buffer. TiO(2) nanoparticle-assisted PCR may be useful for profound reduction of the overall PCR reaction period and for enhanced amplification of DNA amplicons from a variety of samples, including GC-rich templates that are often observed to yield unsatisfactory results.


1 January 2014 in Journal of Molecular Biology
Verified
Journal Article
Closed access
BSBinu K. Sasi
Binu K. Sasi
PSParshuram J. Sonawane
Parshuram J. Sonawane
VGVinayak Gupta
Vinayak Gupta
BSBhavani S. Sahu
Bhavani S. Sahu
NMNitish R. Mahapatra
Nitish R. Mahapatra

14 March 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
BSBinu K. Sasi
Binu K. Sasi
CMClaudio Martines
Claudio Martines
EXElena Xerxa
Elena Xerxa
FPFabiola Porro
Fabiola Porro
HKHilal Kalkan
Hilal Kalkan
Dimitar EfremovDimitar Efremov
Dimitar Efremov

9 December 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
BSBinu Sasi
Binu Sasi
PEPurushoth Ethiraj
Purushoth Ethiraj
JMJamie Myers
Jamie Myers
ALAn-Ping Lin
An-Ping Lin
SJShoulei Jiang
Shoulei Jiang
RARicardo C. T. Aguiar
Ricardo C. T. Aguiar